The architecture of molecular networks around proteins of clinical interest reveal important clues of cellular organization, function and therapeutics strategy.
Most proteins interact with others to accomplish their function, sequestered into complexes and pathways. True network behavior involving structure-, sequence- and ligand-based druggability is the next frontier.
Vistara’s technology holistically observes the effect of the interactome on protein behavior. Proteomics data from cells of interest are used to connect form with function and for observing cross-talk using informatics.
Empirical observations of the network wiring around proteins of clinical interest can uniquely point to the weakest link for drug interventional studies.
Some functional isotypes of the protein may be inherently more 'druggable' than others. Observing proteins dialing in or out of a baseline protein network represent biomarkers of drug action useful for compound evolution studies.
Vistara’s proteomics process is uniquely suited for observing the molecular changes accompanying treatment of cells with drug candidates. A baseline map of untreated cells is compared with maps from drug-treated cells.
Differing network environments across cell-types emerge from distinct network partners and PTMs, which may have impacts on efficacy or resistance to drugs.
Front-end informatics or other 'omics' approaches do not report on network composition. Cell-specific domain function with distinct network partners or co-regulatory proteins, is a hallmark of protein function.
Vistara’s scalable PINsight process identifies proteins and their interaction partners de novo. These networks serve as biomarkers to distinguish players in different cells and observe effects of drugs from a network perspective.
Large scale proteomic approaches are needed to navigate the complexity of the proteome. Deep molecular insights from them can provide a better understanding of aberrant proteins as well as suggest strategies for intervention, such as, drug target or candidate selection or genomic modifications.
Our proprietary proteomics platform offers the unique ability to interrogate and modulate protein networks with de novo identification, at scale, while preserving cell-specific regulatory controls - PTMs, domain-specificity, alternative splicing, and turnover. Observing response in cells in different physiological states help identify rogue proteins, targets, and drug candidates.